Market Overview

Arena Pharma Upgraded Ahead Of Clinical Data Release

Share:
Arena Pharma Upgraded Ahead Of Clinical Data Release

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) received an upgrade from Wall Street on Wednesday as it awaits Phase 2 data for the S1P modulator etrasimod in ulcerative colitis.

The Analyst

Wells Fargo's Jim Birchenough upgraded Arena Pharmaceuticals from Market Perform to Outperform and increased the price target for the stock from $19 to $53.

The Thesis

Wells Fargo upgraded the stock following significant progress in 2017 on ralinepag for pulmonary arterial hypertension, a drug that could be approved due to a more positive FDA environment, Birchenough said. (See the analyst's track record here.) 

The analyst also expressed optimism ahead of Phase 2 data for S1P modulator etrasimod in ulcerative colitis. Recent data from competing S1P modulator ozanimod lowered the bar for differentiation, Birchenough said.

"We believe that both asssets could attract large pharma interest and have greater faith in current management to realize appropriate pipeline value," he said.

Proof-of-biology for selective S1P modulator etrasimod has already been established, with lymphocyte reductions of 67 percent —comparable to the approved S1P modulator GILENYA and the emerging S1P modulator ozanimod, Birchenough said. 

The analyst estimates peak ralinepag sales of $600 million, with a probability-adjusted net present value of $25 per share, assuming a 65-percent likelihood of success.

Assuming positive data, the peak sales estimate of $1 billion for etrasimod may be conservative in the context of $3.3 billion in sales of the competitor GILENYA, Birchenough said. Wells Fargo assigns a net present value estimate of $25 per share for etrasimod, assuming a 55-percent likelihood of success.

The Price Action

Arena Pharmaceuticals closed Wednesday up almost 11 percent higher at $40.17. 

Related Links: 

Benzinga's Top Upgrades, Downgrades For January 3, 2018 

Why Arena Is Taking Center Stage Today 

Latest Ratings for ARNA

DateFirmActionFromTo
Apr 2019MaintainsOutperformOutperform
Dec 2018Initiates Coverage OnBuy
Nov 2018MaintainsOutperformOutperform

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Jim Birchenough Wells FargoAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (ARNA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LOWRBC CapitalMaintains129.0
MARRBC CapitalMaintains148.0
CRLSunTrust Robinson HumphreyMaintains162.0
CFRSunTrust Robinson HumphreyMaintains105.0
ZYNEJefferiesAssumes11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

A Durable Value Strategy In This ETF

Tesla Misses Model 3 Delivery Estimates, Posts Best-Ever Quarter For Models S, X